MediciNova Receives Notice Of Allowance From The Canadian Intellectual Property Office For A New Patent Application Covering The Combination Of MN-166 And Riluzole For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)
Portfolio Pulse from Benzinga Newsdesk
MediciNova has received a notice of allowance from the Canadian Intellectual Property Office for a new patent application. The patent covers the combination of MN-166 and Riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
October 11, 2023 | 6:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MediciNova's new patent application for the combination of MN-166 and Riluzole for ALS treatment has been allowed by the Canadian Intellectual Property Office.
The allowance of the new patent application is a positive development for MediciNova. It strengthens the company's intellectual property portfolio and potentially opens up a new revenue stream from the treatment of ALS. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100